CANNABIS CULTURE – “It is well understood that people with schizophrenia should not take large dosages of psychedelics because it is destabilizing,” says Mark Haden, Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) in Canada. “But we don’t know the effect of small dosages and how that can impact them.”
The future of psychosis treatment took a new turn when Haden met a young man named “John Doe,” who had experience in microdosing for his psychosis. Several years ago, Doe had reached out to MAPS looking to tell a fascinating story. The email made its way to Haden, and the two decided to meet for lunch. Doe began to tell Haden about his harrowing journey, discussing his extensive battle with schizophrenia throughout his teens and young adult life, the extreme anguish of dealing with negative voices in his head every day, and the failure of traditional medications and intoxicants to improve his symptoms.
Doe told Haden, “Everything was always my fault, and the blame was always 100% on me. I was seriously flawed, and the voices pointed this out to me all day. I had no way to escape them, and they were getting stronger and darker.” But